TORONTO, ONTARIO--(Marketwired - Nov. 11, 2014) - BlueOcean NutraSciences Inc. (TSX VENTURE:BOC) ("BlueOcean" or the "Company") is pleased to announce that it has continued to expand its intellectual property portfolio with additional patent application filings.
"BlueOcean's strategy of forming partnerships with strategic partners to develop and commercialize specialty astaxanthin and omega 3 products for the nutraceutical markets is augmented by our own innovations which we are capturing through a growing I.P. portfolio," said BlueOcean's CEO, Gavin Bogle.
BlueOcean's patent portfolio now includes:
Canadian Patent 2,271,170, US Patent 6,209,855, European Patent 1,173,271, Australian Patent 778,289, US Patent 6,436,290 and US Patent 7,537,200 covering unique methods of dramatically increasing microalgae growth yields which are under exclusive license to BlueOcean;
U.S. Patent Application No.: 62/072,865 claiming natural source highly oxygenated drinks comprising fatty acids;
U.S. Patent Application Nos.: 62/061,763 and 61/995,416 - claiming methods and Apparatus for Growing Microalgae;
U.S. Patent Application No.: 62/063,623 claiming formulations of Omega Oils;
U.S. Patent Application No.: 61/987,539 - claiming natural Shrimp Source Extracts Comprising Fatty Acids and Astaxanthin;
U.S. Patent 8,030,348; U.S. Patent 8,278,351; U.S. Patent 8,383,675, U.S. Patent 6,800,299, and Canadian patent, CA 2,493,888 under exclusive license for BlueOcean's shrimp oils.
About BlueOcean NutraSciences Inc.
BlueOcean NutraSciences Inc. is a Canadian listed public company (TSXV:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Krill (and now shrimp) oil and Omega-3 Algal oil health and wellness markets. BlueOcean is developing specialty oil products including AstaShrimp™ and AlgaOmega™. BlueOcean owns 50% of the participating and voting rights in 70717 Newfoundland and Labrador Ltd, a joint venture with a major Atlantic Canada shrimp processor that provides the shrimp feedstock for the extraction of AstaShrimp™, and BlueOcean wholly owns its AlgaOmega™ product line.
The natural oils to be used in AstaShrimp™ contains very high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. AstaShrimp™ will be targeted at the high value and rapidly growing natural astaxanthin market which is expected to grow to over $700M by 2017. AlgaOmega™ oil is a vegetarian, non-GMO omega-3 algal oil containing high levels of EPA with DHA and is targeted at the rapidly growing omega-3 algal oil ingredient market that is currently valued at $500M and growing at 14% CAGR.
Forward Looking Statements
This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.